Company Description
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.
It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.
The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index.
Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Country | United States |
| Founded | 1992 |
| Industry | Asset Management |
| Sector | Financials |
| CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Contact Details
Address: 1900 Market Street, Suite 200 Philadelphia, Pennsylvania 19103 United States | |
| Phone | (617) 772-8515 |
Stock Details
| Ticker Symbol | HQL |
| Exchange | NYSE |
| Reporting Currency | USD |
| CIK Code | 0000884121 |
| CUSIP Number | 87911K100 |
| ISIN Number | US87911K1007 |
| Employer ID | 04-3147016 |
| SIC Code | 0000 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel R. Omstead M.S, Ph.D. | Principal Executive Officer, President and Trustee |
| Peter Branner | Chief Investment Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | N-CSRS | Filing |
| Jun 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 29, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| May 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 29, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Feb 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |